A state-selected continuous wave laser excitation method for determining CO2's rotational state distribution in a supersonic molecular beam.

State-resolved experiments can provide fundamental insight into the mechanisms behind chemical reactions. Here, we describe our methods for characterizing state-resolved experiments probing the outcome of the collision between CO2 molecules and surfaces. We create a molecular beam from a supersonic expansion that passes through an ultra-high vacuum system. The CO2 is vibrationally excited by a continuous wave infrared (IR) laser using rapid adiabatic passage. We attenuate the fractional excitation using a CO2 absorption cell in the IR beam path. We combine Monte Carlo simulations and molecular beam energy measurements to find the initial rotational state distribution of the molecular beam. We find that our pure CO2 beam from a 300 K source has a rotational temperature of ∼26 K.

Spectroscopic investigation of a Co(0001) model catalyst during exposure to H2 and CO at near-ambient pressures.

Cobalt catalysts, although already used industrially for Fischer-Tropsch synthesis, are prone to a number of deactivation mechanisms such as oxidation of the active phase, and the deposition of carbon and reaction products. We have performed near-ambient-pressure X-ray photoelectron spectroscopy on Co(0001) model catalysts during exposure to gases relevant to Fischer-Tropsch synthesis, i.e., CO and H2, at 0.25 mbar total pressure. At this pressure, CO seems to be more efficient at keeping the Co(0001) surface metallic than H2, which is the opposite behavior as reported in the literature for other pressure ranges. We offer an interpretation of these differences based on the preferred adsorption and dissociation sites of CO and H2 compared to the oxidizing agent water (present as impurity in the gas feed and one of the products of the reaction). Additionally, detailed carbon spectra measured at the HIPPIE beamline of MAX IV allow for the distinction of different adsorbed species: CO and COx species are present in correlation to the presence of oxygen on the surface. Carbidic carbon and graphitic carbon can both be removed by hydrogen, whereas adsorbed hydrocarbons possibly poison the surface.

Scaling Platinum-Catalyzed Hydrogen Dissociation on Corrugated Surfaces.

We determine absolute reactivities for dissociation at low coordinated Pt sites. Two curved Pt(111) single-crystal surfaces allow us to probe either straight or highly kinked step edges with molecules impinging at a low impact energy. A model extracts the average reactivity of inner and outer kink atoms, which is compared to the reactivity of straight A- and B-type steps. Local surface coordination numbers do not adequately capture reactivity trends for H2 dissociation. We utilize the increase of reactivity with step density to determine the area over which a step causes increased dissociation. This step-type specific reactive area extends beyond the step edge onto the (111) terrace. It defines the reaction cross-section for H2 dissociation at the step, bypassing assumptions about contributions of individual types of surface atoms. Our results stress the non-local nature of H2 interaction with a surface and provide insight into reactivity differences for nearly identical step sites.

Heterogeneous Catalytic Oxidation of Ammonia by Various Transition Metals.

A well-known demonstration is adapted to simplify the illustration of heterogeneous catalytic oxidation of ammonia. Various metal catalyst wires are placed above the liquid level in a flask containing concentrated ammonia. After brief preheating, some metal wires continue to glow, providing visual evidence of an overall exothermic reaction taking place at the catalyst surface. Thermal heating by a butane flame prior to insertion and in situ resistive heating using a power supply yield identical results. Active catalysts are the group 9 and 10 elements Rh, Ir, Pd, and Pt. Besides the illustration of the Sabatier principle, the effect of the ammonia-to-oxygen ratio can also be visualized, and active metals vary in the production of a grayish smoke. These observations provide a starting point to discuss catalytic selectivity, a topic of great relevance to industrial catalytic oxidation of ammonia.

It's not just the defects - a curved crystal study of H2O desorption from Ag.

We investigate water desorption from hydrophobic surfaces using two curved Ag single crystals centered at (111) and (001) apices. On these types of crystals the step density gradually increases along the curvature, allowing us to probe large ranges of surface structures in between the (001), (111) and (110) planes. Subtle differences in desorption of submonolayer water coverages point toward structure dependencies in water cluster nucleation. The B-type step on hydrophobic Ag binds water structures more strongly than adjacent (111) planes, leading to preferred desorption from steps. This driving force is smaller for A-type steps on (111) terraces. The A'-type step flanked by (001) terraces shows no indication of preferred desorption from steps. Extrapolation to the (311) surface, not contained within either curved surface, demonstrates that both A- and A'-type steps can be regarded chemically identical for water desorption. The different trends in desorption temperature on the two crystals can thus be attributed to stronger water adsorption at (001) planes than at (111) planes and identical to adsorption at the step. These results show that our approach to studying the structure dependence of water desorption is sensitive to variations in desorption energy smaller than 'chemical accuracy', i.e. 1 kcal mol-1.

Steps on Pt stereodynamically filter sticking of O2.

Low coordinated sites on catalytic surfaces often enhance reactivity, but the underlying dynamical processes are poorly understood. Using two independent approaches, we investigate the reactivity of O2 impinging onto platinum and resolve how step edges on (111) terraces enhance sticking. At low incident energy, the linear dependence on step density, independence of step type, and insensitivity to O2's molecular alignment show that trapping into a physisorbed state precedes molecular chemisorption and dissociation. At higher impact energies, direct molecular chemisorption occurs in parallel on steps and terraces. While terraces are insensitive to alignment of the molecule within the (111) plane, steps favor molecules impacting with their internuclear axis parallel to the edge. Stereodynamical filtering thus controls sticking and dissociation of O2 on Pt with a twofold role of steps.

Site-specific reactivity of molecules with surface defects-the case of H2 dissociation on Pt.

The classic system that describes weakly activated dissociation in heterogeneous catalysis has been explained by two dynamical models that are fundamentally at odds. Whereas one model for hydrogen dissociation on platinum(111) invokes a preequilibrium and diffusion toward defects, the other is based on direct and local reaction. We resolve this dispute by quantifying site-specific reactivity using a curved platinum single-crystal surface. Reactivity is step-type dependent and varies linearly with step density. Only the model that relies on localized dissociation is consistent with our results. Our approach provides absolute, site-specific reaction cross sections.

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer's disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Abeta). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. Infusions were generally well-tolerated. Anti-Abeta antibodies in the serum from AD patients increased in proportion to IVIg dose and had a shorter half-life than anti-hepatitis antibodies and total IgG. Plasma Abeta levels increased transiently after each infusion. Cerebrospinal fluid Abeta decreased significantly at 6 months, returned to baseline after washout and decreased again after IVIg was re-administered for an additional 9 months. Mini-mental state scores increased an average of 2.5 points after 6 months, returned to baseline during washout and remained stable during subsequent IVIg treatment. Our findings confirm and extend those obtained by Dodel et al. [Dodel, R.C., Du, Y., Depboylu, C., Hampel, H., Frolich, L., Haag, A., Hemmeter, U., Paulsen, S., Teipel, S.J., Brettschneider, S., Spottke, A., Nolker, C., Moller, H.J., Wei, X., Farlow, M., Sommer, N., Oertel, W.H., 2004. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472-1474] from a 6-month trial of IVIg in 5 AD patients and justify further studies of IVIg for treatment of AD.

Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.

The M-protein is the major reference measure for response in multiple myeloma (MM) and its correct interpretation is key to clinical management. The emergence of oligoclonal banding is recognized as a benign finding in the postautologous stem cell transplantation setting (ASCT) for MM but its significance during non-myeloablative therapy is unknown. In a study of the immunomodulatory combination BiRD, (lenalidomide and dexamethasone with clarithromycin), we frequently detected the emergence of mono- and oligo-clonal immunoglobulins unrelated to the baseline diagnostic M-protein. The new M-proteins seen on serum immunofixation electrophoresis were clearly different in either heavy or light chain component(s) from the original M-spike protein and were termed atypical serum immunofixation patterns (ASIPs). Overall, 24/72 (33%) patients treated with BiRD developed ASIPs. Patients who developed ASIPs compared with patients treated with BiRD without ASIPs, had a significantly greater overall response (100% vs. 85%) and complete response rates (71% vs. 23%). ASIPs were not associated with new clonal plasma cells or other lymphoproliferative processes, and molecular remissions were documented. This is the first time this phenomenon has been seen with regularity in non-myeloablative therapy for MM. Analogous to the ASCT experience, ASIPs do not signal incipient disease progression, but rather herald robust response.

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma. Patients received BiRD in 28-day cycles. Dexamethasone (40 mg) was given orally once weekly, clarithromycin (500 mg) was given orally twice daily, and lenalidomide (25 mg) was given orally daily on days 1 to 21. Objective response was defined by standard criteria (ie, decrease in serum monoclonal protein [M-protein] by at least 50%, and a decrease in urine M-protein by at least 90%). Of the 72 patients enrolled, 65 had an objective response (90.3%). A combined stringent and conventional complete response rate of 38.9% was achieved, and 73.6% of the patients achieved at least a 90% decrease in M-protein levels. This regimen did not interfere with hematopoietic stem-cell harvest. Fifty-two patients who did not go on to receive transplants received continued therapy (complete response, 37%; very good partial response, 33%). The major adverse events were thromboembolic events, corticosteroid-related morbidity, and cytopenias. BiRD is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed multiple myeloma. This trial was registered at www.clinicaltrials.gov as #NCT00151203.

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.

Data on 72 patients receiving lenalidomide/dexamethasone for multiple myeloma (MM) was used to determine the factors that are associated with lenalidomide-induced myelosuppression. Eight of 14 patients with grade > or =3 myelosuppression had baseline creatinine clearance (CrCl) < or =0.67 ml/s. Kaplan-Meier analysis by log-rank test demonstrated a significant association (P < 0.0001) between renal insufficiency and time to myelosuppression (hazard ratio = 8.4; 95% confidence interval 2.9-24.7, P = 0.0001). Therefore, CrCl is inversely associated with significant myelosuppression. Caution should be exercised when lenalidomide therapy is commenced and CrCl should be incorporated as a determinant of the initial dosing of lenalidomide in MM patients.

Gadodiamide administration causes spurious hypocalcemia.

PURPOSE: To evaluate the prevalence of spurious hypocalcemia after gadodiamide-enhanced magnetic resonance (MR) imaging. MATERIALS AND METHODS: Eight hundred ninety-six inpatients with available serum calcium data obtained before and after gadodiamide-enhanced MR imaging were identified. Changes in serum calcium measurements following gadodiamide administration in 1,049 MR imaging examinations performed in these patients were correlated with gadodiamide dose, renal function, and time between gadodiamide administration and phlebotomy. RESULTS: Following 42 gadodiamide-enhanced examinations, serum calcium measurements spuriously decreased by more than 2 mg/dL (0.5 mmol/L), resulting in laboratory reports of "critical" hypocalcemia (ie, calcium level < 6 mg/dL [1.5 mmol/L]) in 25 examinations. These reduced calcium measurements were correlated with serum creatinine level (r = 0.39, P <.001), gadodiamide dose (r = 0.37, P <.001), and time between gadodiamide injection and phlebotomy (r = -0.28, P <.001). Spurious reductions in calcium measurements after administration of 0.1 mmol of gadodiamide per kilogram of body weight were greater in patients with renal insufficiency (0.6 mg/dL [0.15 mmol/L] +/- 0.5 [0.125, SD]) than in those with normal renal function (0.14 mg/dL [0.035 mmol/L] +/- 0.4 [0.1]) (P <.001). After administration of more than 0.2 mmol/kg of gadodiamide, spurious calcium measurement decreases were greater in patients with renal insufficiency (2.4 mg/dL [0.6 mmol/L] +/- 3.6 [0.9]) than in those with normal renal function (0.4 mg/dL [0.1 mmol/L] +/- 0.7 [0.175]) (P <.001). Patients with renal insufficiency had spuriously low calcium measurements up to 4(1/2) days after gadodiamide administration. Seven patients were inappropriately treated with intravenous calcium and eleven with oral calcium in response to false-positive laboratory reports of critical hypocalcemia. No patient had characteristic symptoms of hypocalcemia or injuries attributed to the inappropriate medical treatment. CONCLUSION: Gadodiamide administration causes spurious hypocalcemia, particularly at doses of 0.2 mmol/kg or higher and in patients with renal insufficiency.